Dr. J. Michael Ryan is Chief Medical Officer of Neurvati Neurosciences and GRIN Therapeutics, overseeing clinical and nonclinical development, medical affairs, and safety. He brings more than 25 years of experience spanning academic medicine, global pharmaceutical companies, and venture-backed biotechnology. His background includes advancing therapies from first-in-human studies through late-stage clinical development across neurological and psychiatric disorders.

Previously, Dr. Ryan co-founded Aliada Therapeutics and served as its Chief Medical Officer, leading clinical development and regulatory strategy through the company’s acquisition by AbbVie. Aliada was formed during his tenure as Entrepreneur-in-Residence at RA Capital Management, where he advised on neuroscience investments, company formation, and development strategy. Before RA Capital, he was Chief Medical Officer at Rodin Therapeutics, which was acquired by Alkermes, and, before Rodin, Chief Medical Officer at Asceneuron. Earlier, he served as Vice President and Neurodegeneration Therapeutic Area Head at Novartis, leading global portfolio strategy and clinical development across neurodegeneration, rare neurological disorders, and psychiatry. Before Novartis, he held development roles at Merck, Wyeth, and Pfizer.

Dr. Ryan began his career in academic medicine on the faculty of the University of Rochester School of Medicine, with a focus on geriatric psychiatry and neuropsychiatry. He earned his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. He completed an internship in internal medicine and a residency in psychiatry at the University of Utah, followed by fellowships in geriatric psychiatry and neuropsychiatry at Dartmouth-Hitchcock Medical Center. He is board certified in psychiatry and geriatric psychiatry.